Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study <scp>MT</scp>‐1186‐<scp>A02</scp>)
Daily edaravone oral suspension did not show superiority and had equivalent safety and tolerability vs. the approved On/Off regimen, reinforcing the appropriateness of the approved dosing regimen.
Authors
- Art Wamil
- Amélia M. Silva (ORCID: https://orcid.org/0000-0002-7524-9914)
- Stephen Apple (ORCID: https://orcid.org/0000-0002-3051-3953)
- Angela Genge (ORCID: https://orcid.org/0000-0001-5587-9946)
- Manabu Doyu (ORCID: https://orcid.org/0000-0002-6264-9927)
- Noah J. Sasson (ORCID: https://orcid.org/0000-0002-3676-1253)
- Jeffrey D. Rothstein (ORCID: https://orcid.org/0000-0003-2001-8470)
- Gen Sobue (ORCID: https://orcid.org/0000-0003-4769-5922)
- Lorne Zinman (ORCID: https://orcid.org/0000-0002-8096-8366)
- Fumihiro Takahashi (ORCID: https://orcid.org/0000-0001-5701-5332)
- Daniel Selness
- Alejandro Salah
- Marvin Chum (ORCID: https://orcid.org/0000-0002-2252-0846)
- Masashi Aoki (ORCID: https://orcid.org/0000-0001-7284-1069)
- Adriano Chiò (ORCID: https://orcid.org/0000-0001-9579-5341)
- Vesna Todorović
- Manabu Hirai
- Hiide Yoshino
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Johns Hopkins University (US)
- Mitsubishi Corporation (United States) (US)
- Aichi Medical University (JP)
- University of Toronto (CA)
- Tohoku University (JP)
- Johns Hopkins Medicine (US)
- McMaster University Medical Centre (CA)
- Health Sciences Centre (CA)
- Mitsubishi Corporation (United Kingdom) (GB)
- Chiba Hospital (JP)
- Biostatistical Consulting (United States) (US)
- University of Turin (IT)
- Nagoya University (JP)
- Rogers (United States) (US)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1002/mus.28448
- Citations
- 3
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 4.17
Funders
- Mitsubishi Tanabe Pharma Corporation